[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644599":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":42,"centralContacts":46,"locations":54,"responsibleParty":87,"collaborators":41,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":41,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":41,"enrollmentInfo":98,"targetDuration":41,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":41,"overallStatus":57,"whyStopped":41,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Hoffmann-La Roche","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Enicepatide Dose 1","EXPERIMENTAL","Participants will receive enicepatide Dose 1.",[13],"Combination Product: Enicepatide",{"label":15,"type":10,"description":16,"interventionNames":17},"Enicepatide Dose 2","Participants will receive enicepatide Dose 2.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Enicepatide Dose 3","Participants will receive enicepatide Dose 3.",[13],{"label":23,"type":24,"description":25,"interventionNames":26},"Placebo","PLACEBO_COMPARATOR","Participants will receive matching placebo.",[27],"Combination Product: Placebo",[29,38],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"COMBINATION_PRODUCT","Enicepatide","Participants will receive enicepatide via subcutaneous (SC) injection as per the schedule in the protocol.",[9,15,19],[35,36,37],"RO7795068","CT-388","RG6640",{"type":30,"name":23,"description":39,"armGroupLabels":40,"otherNames":41},"Participants will receive matching placebo via SC injection as per the schedule in the protocol.",[23],null,[43],{"name":44,"affiliation":5,"role":45},"Clinical Trials","STUDY_DIRECTOR",[47,52],{"name":48,"role":49,"phone":50,"phoneExt":41,"email":51},"Reference Study ID Number: YC46401 https:\u002F\u002Fforpatients.roche.com No attachments to email below.","CONTACT","888-662-6728 (U.S. Only)","global-roche-genentech-trials@gene.com",{"name":53,"role":49,"phone":41,"phoneExt":41,"email":41},"Fastest response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[55,69,78],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":41},"The First Affiliated Hospital of Ningbo University(Ningbo First Hospital)","RECRUITING","Ningbo","Zhejiang","315010","China","CN",{"type":64,"coordinates":65},"Point",[66,67],121.54945,29.87819,{"lat":67,"lon":66},{"facility":70,"status":57,"city":71,"state":41,"zip":72,"country":61,"countryCode":62,"cosmosGeoPoint":73,"geoPoint":77,"contacts":41},"Peking University People's Hospital","Beijing","100044",{"type":64,"coordinates":74},[75,76],116.39723,39.9075,{"lat":76,"lon":75},{"facility":79,"status":57,"city":80,"state":41,"zip":81,"country":61,"countryCode":62,"cosmosGeoPoint":82,"geoPoint":86,"contacts":41},"Shanghai Fifth People's Hospital Affiliated to Fudan University","Shanghai","201304",{"type":64,"coordinates":83},[84,85],121.45806,31.22222,{"lat":85,"lon":84},{"type":88,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100644599","phase-3-a-study-to-evaluate-the-effects-of-enicepatide-in-participants-with-obesity-or-overweight-with-or-without-type-2-diabetes-100644599",false,"NCT07670416","A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 in Adult Chinese Patients With Obesity or Overweight, With or Without Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Body mass index (BMI) ≥24.0 kilograms per meter squared (kg\u002Fm\\^2) for participants with type 2 diabetes mellitus (T2DM)\n* BMI ≥28.0 kg\u002Fm\\^2 or BMI ≥24.0 and \\\u003C28.0 kg\u002Fm\\^2 and diagnosed with at least one weight-related comorbidity (prediabetes, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, or weight-related cardiovascular disease) for participants without T2DM\n* Agreement to adhere to the contraception requirements\n\nExclusion Criteria:\n\n* History of Type 1 diabetes mellitus (T1DM)\n* Obesity induced by other endocrinologic disorders\n* Any planned major medical procedure or surgery during the study\n* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder\n* Any lifetime history of suicide attempt\n* History of any hematologic conditions that may interfere with HbA1c measurement\n* History of acute or chronic pancreatitis or clinically significant gallbladder disease\n* Treatment with any approved or investigational GLP-1-RA-based therapy within 6 months prior to randomization\n* Treatment with other investigational therapy within 3 months prior to randomization or less than 5 elimination half-lives prior to randomization, whichever is longer\n* Known allergy to any component of the study drug formulation or any other condition that is a contraindication to GLP-1 RAs or GLP-1\u002FGIP RAs","ALL","18 Years",{"count":99,"type":100},300,"ESTIMATED","INTERVENTIONAL",[103],"PHASE3","The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)\u002Fglucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.",[106,107,108],"Obesity","Overweight","Type 2 Diabetes Mellitus (T2DM)","2026-06-22",{"date":111,"type":112},"2026-06-26","ACTUAL",{"date":114,"type":100},"2026-06-25",{"date":116,"type":100},"2028-04-02",{"name":5,"class":6},3]